On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naval Daver of MD Anderson Cancer Center speaks candidly regarding the future of myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) research and treatment. Dr. Daver discusses the increasing value of genetic analysis as well as the push to find new drugs to defeat markers and mutations.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement